U.S. markets closed
  • S&P Futures

    4,344.75
    +27.00 (+0.63%)
     
  • Dow Futures

    34,221.00
    +178.00 (+0.52%)
     
  • Nasdaq Futures

    14,137.50
    +150.75 (+1.08%)
     
  • Russell 2000 Futures

    1,936.10
    +7.80 (+0.40%)
     
  • Crude Oil

    86.95
    +0.34 (+0.39%)
     
  • Gold

    1,797.90
    +4.80 (+0.27%)
     
  • Silver

    22.77
    +0.10 (+0.44%)
     
  • EUR/USD

    1.1157
    +0.0010 (+0.09%)
     
  • 10-Yr Bond

    1.8070
    -0.0410 (-2.22%)
     
  • Vix

    30.49
    -1.47 (-4.60%)
     
  • GBP/USD

    1.3401
    +0.0020 (+0.15%)
     
  • USD/JPY

    115.3700
    +0.0680 (+0.06%)
     
  • BTC-USD

    37,297.91
    +1,164.59 (+3.22%)
     
  • CMC Crypto 200

    845.07
    +25.56 (+3.12%)
     
  • FTSE 100

    7,554.31
    +84.53 (+1.13%)
     
  • Nikkei 225

    26,720.06
    +549.76 (+2.10%)
     

Why C4 Therapeutics (CCCC) Might Surprise This Earnings Season

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • CCCC

Investors are always looking for stocks that are poised to beat at earnings season and C4 Therapeutics, Inc. CCCC, may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because C4 Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for CCCC in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 59 cents per share for CCCC, compared to a broader Zacks Consensus Estimate of a loss of 60 cents per share. This suggests that analysts have very recently bumped up their estimates for CCCC, giving the stock a Zacks Earnings ESP of +2.32% heading into earnings season.

C4 Therapeutics, Inc. Price and EPS Surprise

C4 Therapeutics, Inc. Price and EPS Surprise
C4 Therapeutics, Inc. Price and EPS Surprise

C4 Therapeutics, Inc. price-eps-surprise | C4 Therapeutics, Inc. Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that CCCC has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for C4 Therapeutics, and that a beat might be in the cards for the upcoming report.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

C4 Therapeutics, Inc. (CCCC) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research